SYRACUSE BIOPHARMA
Syracuse Biopharma was formed in 2017 by Eureka Therapeutics to commercialize Eureka’s proprietary TCR-mimic and antibody-TCR ARTEMIS® programs in China and the ASEAN countries. Syracuse’s clinical programs include Eureka’s anti-AFP ARTEMIS® program for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer, which is currently in a Phase I/II clinical trial in the United States.
SYRACUSE BIOPHARMA
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2017-01-01
Address:
Hong Kong, Hong Kong Island, Hong Kong
Country:
Hong Kong
Status:
Active
Similar Organizations
Genevide
Genevide is a biotech company that specializes in gene research and development.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
More informations about "Syracuse Biopharma"
JW Therapeutics Acquires Syracuse Biopharma and Its In-Licenses …
Jul 20, 2020 Syracuse Biopharma was formed in 2017 by Eureka Therapeutics to commercialize Eureka’s proprietary TCR-mimic and antibody-TCR ARTEMIS® programs in China and the …See details»
JW Therapeutics Acquires Syracuse Biopharma and License to
Jul 20, 2020 Shanghai, China and Emeryville, California, July 20, 2020 – JW Therapeutics, a clinical stage biopharmaceutical company focused on developing, manufacturing and …See details»
Syracuse Biopharma - Ownership and Business Overview - Mergr
Syracuse’s clinical programs include Eureka’s anti-AFP ARTEMIS® program for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer, which is currently in a …See details»
Syracuse Biopharma - Products, Competitors, Financials, …
Syracuse Biopharma was formed in 2017 by Eureka Therapeutics to commercialize Eureka’s proprietary TCR-mimic and antibody-TCR ARTEMIS® programs in China and the ASEAN …See details»
JW Therapeutics acquires Syracuse, licenses Eureka's
Jul 20, 2020 Eureka established Syracuse Biopharma in 2017 to commercialize its TCR-mimic and antibody-TCR Artemis programs in China and ASEAN regions. Terms of the deal were not disclosed in a July 20 news release. Eureka …See details»
JW Therapeutics - Funding, Financials, Valuation & Investors
JW Therapeutics has acquired Syracuse Biopharma on Jul 20, 2020. Which types of acquisition does this organization make most frequently? Show . Acquiree Name . Announced Date . …See details»
JW Therapeutics acquires Syracuse Biopharma - Crunchbase
Jul 20, 2020 Syracuse Biopharma Syracuse Biopharma formed to commercialize Eureka's proprietary TCR-mimic and antibody-TCR ARTEMIS programs. Acquiring Organization: JW …See details»
JW Therapeutics Acquires Syracuse Biopharma - FinSMEs
Jul 26, 2020 JW Therapeutics, a clinical stage biopharmaceutical company focused on developing, manufacturing and commercializing cell therapies for patients in China, acquired Syracuse Biopharma (Hong Kong ...See details»
Syracuse Biopharma Inc Overview - Salary.com
Syracuse Biopharma Inc Information BETA. Headquarters Address: 5858 Horton St Ste 170, Emeryville, California. Phone Number: Data pending, update soon. Revenue: ... The trusted …See details»
Syracuse Biopharma - CB Insights
Jul 20, 2020 See Syracuse Biopharma funding rounds, investors, investments, exits and more. Evaluate their financials based on Syracuse Biopharma's post-money valuation and revenue. …See details»
JW Therapeutics Acquires Syracuse Biopharma and License to …
Jul 20, 2020 JW Therapeutics announced the acquisition of Syracuse Biopharma (Hong Kong) Limited, which includes the license for Eureka Therapeutics’ ARTEMIS antibody TCR and …See details»
JW Therapeutics Acquires Syracuse Biopharma and Its in-Licenses …
Jul 21, 2020 Menu. Deals. DealShot. DealShot Data; What is DealShot? Finley Newsbot; Private EquitySee details»
Syracuse Biopharma - Crunchbase
Syracuse Biopharma formed to commercialize Eureka's proprietary TCR-mimic and antibody-TCR ARTEMIS programs.See details»
JW Therapeutics Acquires Syracuse Biopharma and License to …
Jul 27, 2020 JW Therapeutics, a clinical stage biopharmaceutical company focused on developing, manufacturing and commercializing cell therapies for patients in China, today …See details»
Lotte Biologics Intends to Become a Global CDMO - PROCESS …
Feb 14, 2023 Lotte Biologics has acquired the Syracuse plant in the United States from Bristol Myers Squibb Co. and now plans to expand it by adding ADC contract manufacturing services …See details»
Top Pharmaceutical & Biotechnology Companies in Syracuse
Browse the top Pharmaceutical & Biotechnology companies in Syracuse. Salaries, reviews, and more - all posted by employees working at the top Pharmaceutical & Biotechnology companies …See details»
Pharmaceutical & Biotechnology Companies in Syracuse, NY
Pharmaceutical & Biotechnology • more than 10,000 employees We aspire to be the premier research-intensive biopharmaceutical company in the world. Innovation and scientific …See details»
Syracuse Biopharma - Updates, News, Events, Signals & Triggers
Syracuse Biopharma formed to commercialize Eureka's proprietary TCR-mimic and antibody-TCR ARTEMIS programs.See details»
Peptide Drug Advances Being Made on Syracuse University …
1 day ago All compounds are produced in a campus lab at Syracuse University’s Center for Science and Technology equipped as a sort of mini pharmaceutical design and manufacturing …See details»
Top Biotech & Pharmaceuticals Companies in Syracuse
Bristol Myers Squibb is led by our unique BioPharma strategy that combines the innovation and agility of a biotech with the reach and resources of a major pharma company. Through our …See details»